|1.||Lu, Weiyue: 7 articles (08/2015 - 08/2011)|
|2.||Liu, Min: 4 articles (08/2015 - 12/2013)|
|3.||Shuai, Xin-Tao: 4 articles (11/2012 - 03/2008)|
|4.||Gao, Jie: 3 articles (08/2015 - 12/2013)|
|5.||Xie, Cao: 3 articles (08/2015 - 12/2013)|
|6.||Xie, Zuoxu: 3 articles (08/2015 - 12/2013)|
|7.||Liu, Yunyun: 3 articles (08/2015 - 01/2013)|
|8.||Wen, Xiaojun: 3 articles (08/2015 - 01/2013)|
|9.||Liu, Zhonglin: 3 articles (08/2015 - 01/2013)|
|10.||Hu, Jingyang: 3 articles (08/2015 - 01/2013)|
11/15/2012 - "Our study demonstrated that cRGD-PEG-PEI transported the PEDF gene into endothelia cells more efficiently than PEG-PEI, resulting in more effective inhibitory effects on tumor growth by anti-angiogenesis. "
09/01/2009 - "However, nano-drug without Tyr-RGD appeared in tumor tissue as well as other organs such as livers, lungs, etc. The Tyr-RGD-targeted gene vector Tyr-RGD-PEG-PEI synthesized in this study has good nanoparticle properties and high efficiency of gene-drug encapsulation. "
11/15/2012 - "Accordingly, SW620 tumors from cRGD-PEG-PEI/PEDF-pcDNA3.1 (+)-treated mice expressed more PEDF than that of the control groups. "
12/01/2014 - "In vivo assay demonstrates that the GO-PEG-PEI-CpG complex provides synergistic photothermal and immunological effects under laser irradiation for cancer treatment, which shows the highest efficiency in tumor reduction, implying the excellent therapeutic efficacy of the GO-PEG-PEI-CpG complex in cancer therapy."
11/15/2012 - "PEDF gene delivered by cRGD-PEG-PEI apparently suppressed growth of tumor with a 67.4% reduction and decreased microvessel density in nude mice bearing SW620 human colorectal xenografts. "
|2.||Glioblastoma (Glioblastoma Multiforme)
02/19/2014 - "Therefore, D(RPPREGR)-PEG-PEI appears to be suitable for use as a safe and efficient gene delivery vehicle with potential applications in glioblastoma gene therapy. "
12/15/2013 - "Taken together, the results show that RGERPPR-PEG-PEI could be used as a safe and efficient gene delivery vehicle with potential applications in glioblastoma gene delivery. "
01/02/2012 - "These nanoparticles had a high binding affinity with U87 cells and facilitated targeted gene delivery against intracranial glioblastoma in vivo, thereby leading to a higher gene transfer efficiency compared to the PEG-PEI gene carrier without RGD decoration. "
01/02/2012 - "Considering the contribution of glioblastoma neovasculature to the BBB under angiogenic conditions, our results demonstrated the therapeutic feasibility of treating a brain tumor through mediation of integrin α(v)β(3), as well as the potential of using RGD-PEG-PEI as a targeted gene carrier in the treatment of intracranial glioblastoma."
08/01/2011 - "The biodistribution of RGD-PEG-PEI/pEGFP-N2 complexes in mice bearing subcutaneous glioblastomas were significantly greater than that of RGD-PEI-mPEG/pEGFP-N2 complexes, suggesting a more efficient gene transfection in vivo. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
10/01/2009 - "We incorporated the anticancer compound, 6-hydroxymethyl-1,4-anthracenedione (code name AQ10) into PEG-PEI nanogel, and found that AQ10-encapsulated nanogel PEG-PEI is significantly more effective in altering the growth of Pan 02 (pancreatic cancer) cells compared to AQ10 or nanogel PEG-PEI alone. "
08/01/2009 - "This study revealed a significant increase of cytotoxicity in vitro following the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL treatments in C6 glioma cells. "
02/19/2014 - "An antiglioblastoma assay revealed that D(RPPREGR)-PEG-PEI carrying the therapeutic gene pORF-hTRAIL significantly prolonged the survival time of intracranial U87 glioma-bearing mice from 25 to 30 days. "
12/15/2013 - "Furthermore, the RGERPPR-PEG-PEI/pDNA complex facilitated enhanced transfection efficiency levels, as well as a reduction in cytotoxicity when tested in U87 glioma cells in vitro. "
08/01/2009 - "The C6 glioma cells and animal model were treated by the combined application of FA-PEG-PEI/pCD/5-FC and FA-PEG-PEI/pTRAIL. "
08/01/2009 - "The potency of the FA-PEG-PEI used as a nonviral vector was tested in the FR-expressed C6 glioma cells and Wistar rats. "
01/01/2010 - "The size, surface charge using zeta potential, and morphology via scanning electron microscopy (SEM) of PEG-PEI/siRNA nanoparticles was characterized, and their cytotoxicity, transfection efficiency, and interaction with SGC7901 human gastric carcinoma cells was evaluated. "
04/01/2009 - "This new target strategy of pAFP-TK/GCV suicide gene therapy system in which PEG-PEI Fe(3)O(4) nano-magnetic fluid are used as gene delivery vectors explores a promising area for AFP positive HCC and associated carcinoma therapy."
09/01/2003 - "Specific targeting of ovarian carcinoma cells using pegylated polyethylenimine (PEG-PEI) conjugated to the antigen binding fragment (Fab') of the OV-TL16 antibody, which is directed to the OA3 surface antigen, was the objective of this study. "
01/01/2010 - "To overcome instability and low transfection efficiency, polyethylene glycol-polyethyleneimine (PEG-PEI) was synthesized and investigated as a non-viral carrier of siRNA targeting CD44v6 in gastric carcinoma cells. "
11/28/2006 - "The VEGF siRNA-PEG/PEI PEC micelles effectively silenced VEGF gene expression in prostate carcinoma cells (PC-3) up to 96.5% under an optimized formulation condition. "
|1.||monomethoxypolyethylene glycol (MPEG)
|4.||Ethylene Glycol (Monoethylene Glycol)
|5.||DNA (Deoxyribonucleic Acid)
|6.||Small Interfering RNA (siRNA)
|7.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Interleukin-12 (IL 12)
|9.||Messenger RNA (mRNA)
|2.||Heterologous Transplantation (Xenotransplantation)